Background and objectives: Psoriasis is a chronic immune-mediated skin disease caused by several complex factors, both environmental and genetic, many of which are still not fully understood. Nowadays, several groups of biological drugs are being used for psoriasis treatment. Although these therapies are very effective, they show significant variability in efficacy among individuals. Therefore, there is a need for biomarkers to predict treatment outcomes in order to guide personalized therapeutic decisions. Pharmacogenetics is the study of variations in DNA sequences related to drug response. Materials and Methods: In this article, we review pharmacogenetics studies on the treatment of moderate-to-severe psoriasis focusing on anti-interleukin (IL) 12/23 (ustekinumab) and anti-IL17 drugs (secukinumab and ixekizumab), as well as recent studies concerning anti-TNF drugs. Results: Several polymorphisms have been studied over the years in reference to anti-TNF drugs; some of the most recent studies included the performance of a genome-wide association study (GWAS) and pharmacogenetics studies focused on the optimization of a treatment regimen. Various polymorphisms in different genes have been related to ustekinumab response; among them, the most commonly studied is the HLA-C*06:02 allele. Conclusions: Although not confirmed in some studies, most studies have shown that patients carrying this allele present a significantly higher response rate to ustekinumab. Some polymorphisms have been studied in patients treated with anti-IL17 drugs, mostly related to secukinumab; however, up to now, no association has been found between any of these polymorphisms and response. Nevertheless, further studies involving larger cohorts are needed in order to confirm these results before the implementation of this biomarker in clinical practice.
Background and objectives: Psoriasis is a chronic immune-mediated skin disease caused by several complex factors, both environmental and genetic, many of which are still not fully understood. Nowadays, several groups of biological drugs are being used for psoriasis treatment. Although these therapies are very effective, they show significant variability in efficacy among individuals. Therefore, there is a need for biomarkers to predict treatment outcomes in order to guide personalized therapeutic decisions. Pharmacogenetics is the study of variations in DNA sequences related to drug response. Materials and Methods: In this article, we review pharmacogenetics studies on the treatment of moderate-to-severe psoriasis focusing on anti-interleukin (IL) 12/23 (ustekinumab) and anti-IL17 drugs (secukinumab and ixekizumab), as well as recent studies concerning anti-TNF drugs. Results: Several polymorphisms have been studied over the years in reference to anti-TNF drugs; some of the most recent studies included the performance of a genome-wide association study (GWAS) and pharmacogenetics studies focused on the optimization of a treatment regimen. Various polymorphisms in different genes have been related to ustekinumab response; among them, the most commonly studied is the HLA-C*06:02 allele. Conclusions: Although not confirmed in some studies, most studies have shown that patients carrying this allele present a significantly higher response rate to ustekinumab. Some polymorphisms have been studied in patients treated with anti-IL17 drugs, mostly related to secukinumab; however, up to now, no association has been found between any of these polymorphisms and response. Nevertheless, further studies involving larger cohorts are needed in order to confirm these results before the implementation of this biomarker in clinical practice.
Authors: M Papini; F Cusano; M Romanelli; M Burlando; G Stinco; G Girolomoni; K Peris; C Potenza; A Offidani; M Bartezaghi; E Aloisi; A Costanzo Journal: Br J Dermatol Date: 2019-05-29 Impact factor: 9.302
Authors: Marc Julià; Antonio Guilabert; Francisco Lozano; Belén Suarez-Casasús; Nemesio Moreno; Jose Manuel Carrascosa; Carlos Ferrándiz; Edurne Pedrosa; Mercè Alsina-Gibert; José Manuel Mascaró Journal: JAMA Dermatol Date: 2013-09 Impact factor: 10.282
Authors: J M P A van den Reek; M J H Coenen; M van de L'Isle Arias; J Zweegers; D Rodijk-Olthuis; J Schalkwijk; S H Vermeulen; I Joosten; P C M van de Kerkhof; M M B Seyger; P L J M Zeeuwen; E M G J de Jong Journal: Br J Dermatol Date: 2017-04-10 Impact factor: 9.302
Authors: Selma Atalay; Juul M P A van den Reek; Lieke J van Vugt; Marisol E Otero; Peter C M van de Kerkhof; Alfons A den Broeder; Wietske Kievit; Elke M G J de Jong Journal: BMC Dermatol Date: 2017-05-08
Authors: Gerd R Burmester; Remo Panaccione; Kenneth B Gordon; Melissa J McIlraith; Ana P M Lacerda Journal: Ann Rheum Dis Date: 2012-05-05 Impact factor: 19.103
Authors: Marija V Medovic; Vladimir Lj Jakovljevic; Vladimir I Zivkovic; Nevena S Jeremic; Jovana N Jeremic; Sergey B Bolevich; Ana B Ravic Nikolic; Vesna M Milicic; Ivan M Srejovic Journal: Oxid Med Cell Longev Date: 2022-03-12 Impact factor: 6.543
Authors: Giuseppe Fabrizio Amoruso; Steven Paul Nisticò; Luigi Iannone; Emilio Russo; Giuseppe Rago; Cataldo Patruno; Luigi Bennardo Journal: Healthcare (Basel) Date: 2021-05-07